- Conditions
- Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions
- Interventions
- data collection
- Drug
- Lead sponsor
- Paul Szabolcs
- Other
- Eligibility
- 2 Months to 60 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 89
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Autoimmune Diseases, Ulcerative Colitis, Multiple Sclerosis, Scleroderma, Ankylosing Spondylitis, Celiac Disease, Non-radiographic Axial Spondyloarthritis (Nr-axSpA), Crohn&Amp;#39;s Disease, Birdshot Chorioretinitis
- Interventions
- Companion blood samples with procedure
- Procedure
- Lead sponsor
- TScan Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 238 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 11
- States / cities
- Orange, California • Sherman Oaks, California • Skokie, Illinois + 7 more
- Conditions
- B-cell Mediated Autoimmune Disorders
- Interventions
- Azercabtagene zapreleucel (azer-cel)
- Drug
- Lead sponsor
- TG Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 8
- States / cities
- La Jolla, California • Ann Arbor, Michigan • Omaha, Nebraska + 5 more
- Conditions
- Diabetic Retinopathy, Age-Related Macular Degeneration (AMD), Uveitis
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 4 Years and older
- Enrollment
- 609 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Autoimmune Diseases, Lupus Erythematosus, Systemic, Communicable Diseases
- Interventions
- Not listed
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2028
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Ocular Inflammation, Crystalline Lens; Chalcosis, Intraocular Lens Complication
- Interventions
- Cymbathera One System
- Device
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Cystoid Macular Edema, Uveitis
- Interventions
- Vitamin E
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Autoimmune Disease, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune, Multiple Sclerosis Transplant, MS Stem Cell Transplant, Multiple Sclerosis Stem Cell Transplant, Stiff Person Syndrome, HCT for Neurologic Autoimmune Disorders, CIDP Transplant, Myasthenia Gravis Transplant, Autoimmune Nervous System Disorder, Central Nervous System Vasculitis, Cerebellar Degeneration, Chronic Inflammatory Demyelinating Polyneuropathy, Lambert Eaton Myasthenic Syndrome, Myasthenia Gravis, Neuromyelitis Optica, Opsoclonus Myoclonus Syndrome, Rasmussen Subacute Encephalitis
- Interventions
- Anti-Thymocyte Globulin, Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine, Etoposide, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Prednisone, Syngeneic Bone Marrow Transplantation
- Biological · Procedure · Drug + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 71 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2030
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Seattle, Washington
- Conditions
- Glaucoma
- Interventions
- Trabeculectomy with mitomycin c, Ex-Press mini shunt with mitomycin c
- Procedure
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Dry Eye Disease
- Interventions
- Vevye®, Xiidra®
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 378 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 8
- States / cities
- Newport Beach, California • Louisville, Kentucky • Andover, Massachusetts + 5 more
- Conditions
- Non-infectious Uveitis
- Interventions
- AIN457, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 10
- States / cities
- Beverly Hills, California • Atlanta, Georgia • Louisville, Kentucky + 7 more
- Conditions
- Oral Lichen Planus, Mucous Membrane Pemphigoid, Pemphigus Vulgaris, Chronic Graft-versus-host-disease
- Interventions
- dexamethasone 0.5mg/5ml solution, dexamethasone 0.5mg/5ml solution in Mucolox™
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Uveitis, Scleritis
- Interventions
- tofacitinib
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Diabetic Macular Edema
- Interventions
- nepafenac 0.1% drops, Nepafenac Vehicle
- Drug · Other
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 32
- States / cities
- Loma Linda, California • Palm Springs, California • Santa Barbara, California + 29 more
- Conditions
- Ocular Inflammatory Disease, Uveitis
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 6 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
- Interventions
- Specimen sample
- Diagnostic Test
- Lead sponsor
- Sanguine Biosciences
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 20,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Waltham, Massachusetts
- Conditions
- Eye Disease, Inflammation, Uveitis
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1987 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Allergic Conjunctivitis
- Interventions
- Manuka honey
- Drug
- Lead sponsor
- Toyos Clinic
- Other
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 2
- States / cities
- Germantown, Tennessee • Nashville, Tennessee
- Conditions
- Uveitis
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 8 Years to 100 Years
- Enrollment
- 343 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Sjogren's Disease
- Interventions
- Administration of Lotemax
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 50 Years to 70 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Anterior Uveitis (AU), Birdshot Chorioretinitis, Behcet Disease, Herpes Simplex Virus, Juvenile Idiopathic Arthritis (JIA), Spondyloarthritis (SA), Sarcoidosis, Posterior Vitreous Detachment
- Interventions
- Not listed
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 5 Years to 85 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Glaucoma
- Interventions
- Prednisolone 1%, Ketorolac, Artificial Tears
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 2
- States / cities
- Miami, Florida • Pittsburgh, Pennsylvania
- Conditions
- Optic Neuritis, Myelitis, Myelitis, Transverse
- Interventions
- High-dose corticosteroids (HDCS), High-dose corticosteroids (HDCS) and PLEX
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 382 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Loma Linda, California + 27 more
- Conditions
- Uveitis, Vasculitis, Ocular Inflammatory Disease
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland